Department of Clinical Pharmacy, Institute of Pharmacy, Innsbruck University, Innrain 80, 6020, Innsbruck, Austria.
Int J Clin Pharm. 2024 Jun;46(3):751-754. doi: 10.1007/s11096-024-01705-1. Epub 2024 Mar 12.
The current academic debate on the use of artificial intelligence (AI) in research and teaching has been ongoing since the launch of ChatGPT in November 2022. It mainly focuses on ethical considerations, academic integrity, authorship and the need for new legal frameworks. Time efficiencies may allow for more critical thinking, while ease of pattern recognition across large amounts of data may promote drug discovery, better clinical decision making and guideline development with resultant consequences for patient safety. AI is also prompting a re-evaluation of the nature of learning and the purpose of education worldwide. It challenges traditional pedagogies, forcing a shift from rote learning to more critical, analytical, and creative thinking skills. Despite this opportunity to re-think education concepts for pharmacy curricula several universities around the world have banned its use. This commentary summarizes the existing debate and identifies the consequences and opportunities for clinical pharmacy research and education.
自 2022 年 11 月 ChatGPT 发布以来,关于在研究和教学中使用人工智能(AI)的当前学术争论一直在进行。它主要集中在伦理考虑、学术诚信、作者身份和新法律框架的需求上。时间效率可能允许更多的批判性思维,而在大量数据中进行模式识别的便利性可能会促进药物发现、更好的临床决策制定和指南制定,从而对患者安全产生影响。人工智能也在促使全球范围内重新评估学习的本质和教育的目的。它挑战了传统的教学法,迫使从死记硬背向更批判性、分析性和创造性思维技能转变。尽管有机会重新思考药学课程的教育理念,但全球仍有几所大学禁止使用 AI。本评论总结了现有的争论,并确定了其对临床药学研究和教育的影响和机遇。